ATR and colorectal carcinoma: A drug-screening with 25 DDR targeting/triggering agents, including replication poisons commonly used to treat CRC in clinical practice, revealed that neoR-CRC-SCs were significantly more resistant than their sensitive counterparts (hereafter referred to as SENS) to the CHK1 inhibitor rabusertib and to the ATR inhibitors VE-821 and berzosertib (Fig. 1d, e; Supplementary Fig. S1e, f).